HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stephenson, A. Articles by Tullis, E. Search for Related Content PubMed PubMed Citation Articles by Stephenson, A. Articles by Tullis, E. Agricola Articles by Stephenson, A. Articles by Tullis, E.

Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis^1,2

¹ From the Toronto Adult Cystic Fibrosis Centre, St Michael's Hospital, Toronto, Canada (AS, MB, RR, and ET), and the Research Institute, The Hospital for Sick Children, Toronto, Canada (EA and MC)

Background: Vitamin D deficiency is increasingly being recognized and treated in patients with cystic fibrosis, although the treatment guidelines are not proven and the effectiveness of vitamin D preparations is untested.

Objectives: The aims of this study were to determine the prevalence of 25-hydroxyvitamin D [25(OH)D] deficiency in a large cohort of adults with cystic fibrosis and to evaluate the effectiveness of supplementation with cholecalciferol.

Design: In this retrospective cohort design, baseline 25(OH)D concentrations were measured, and the effects of clinical interventions that involved either counseling on compliance or increasing supplemental cholecalciferol on serum 25(OH)D concentrations in those subjects with baseline concentrations 50 nmol/L were evaluated.

Results: Of 360 adults with cystic fibrosis, 249 (69%) had baseline 25(OH)D concentrations 50 nmol/L, despite similar levels of supplementation. The lowest 25(OH)D concentrations were seen in younger subjects who had lower body mass indexes and less pulmonary function. Serum 25(OH)D concentrations increased significantly (P < 0.0001)—from 35.5 ± 10.1 to 62.5 ± 19.1 nmol/L—in 92% of the subjects after the intervention. The subjects with baseline 25(OH)D concentrations < 25 nmol/L had the largest increase in serum 25(OH)D (P = 0.02).

Conclusions: A significant proportion of adults with cystic fibrosis have serum 25(OH)D concentrations 50 nmol/L. Cholecalciferol increases serum 25(OH)D concentrations significantly, and the maximum response occurs in persons with the lowest baseline concentrations.

Key Words: 25-Hydroxyvitamin D • cystic fibrosis • supplementation

This article has been cited by other articles:

				N. B. Khazai, S. E. Judd, L. Jeng, L. L. Wolfenden, A. Stecenko, T. R. Ziegler, and V. Tangpricha Treatment and Prevention of Vitamin D Insufficiency in Cystic Fibrosis Patients: Comparative Efficacy of Ergocalciferol, Cholecalciferol, and UV Light J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2037 - 2043. [Abstract] [Full Text] [PDF]

				E. Robberecht and S. Vandewalle Cholecalciferol and 25-hydroxyvitamin D concentrations in adults with cystic fibrosis Am. J. Clinical Nutrition, January 1, 2008; 87(1): 190 - 190. [Full Text] [PDF]

				A. Stephenson Reply to E Robberecht and S Vandewalle Am. J. Clinical Nutrition, January 1, 2008; 87(1): 190 - 191. [Full Text] [PDF]